Journal of Drugs in Dermatology最新文献

筛选
英文 中文
Response To "The Potential Impact of Off-Label Medication Use on Patient Access: A Cross-Sectional Survey of Minoxidil Availability". 回应 "标示外用药对患者就医的潜在影响:米诺地尔可用性横断面调查"。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01
Ambika Nohria, Deesha Desai, Hailey Konisky, Jerry Shapiro, Kristen I Lo Sicco
{"title":"Response To \"The Potential Impact of Off-Label Medication Use on Patient Access: A Cross-Sectional Survey of Minoxidil Availability\".","authors":"Ambika Nohria, Deesha Desai, Hailey Konisky, Jerry Shapiro, Kristen I Lo Sicco","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 2.6% Benzoyl Peroxide AV Cleanser Specifically Designed for Sensitive Skin Offers Good Efficacy and Tolerability. 专为敏感性皮肤设计的 2.6% 过氧苯甲酰 AV 清洁剂具有良好的功效和耐受性。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.8219
James Q Del Rosso, Thu Q Nguyen, Christine Emesiani, Matthew Meckfessel
{"title":"A 2.6% Benzoyl Peroxide AV Cleanser Specifically Designed for Sensitive Skin Offers Good Efficacy and Tolerability.","authors":"James Q Del Rosso, Thu Q Nguyen, Christine Emesiani, Matthew Meckfessel","doi":"10.36849/JDD.8219","DOIUrl":"https://doi.org/10.36849/JDD.8219","url":null,"abstract":"<p><strong>Background: </strong>Mild-to-moderate acne vulgaris (AV) is common among adults, and benzoyl peroxide (BPO) has a long history of efficacy in reducing AV lesions. The efficacy of BPO is comparable for concentrations from 2.5% to 10% used as leave-on therapy, but tolerability is usually best at lower concentrations formulated in well-designed vehicles and with newer formulation methods such as micronization. This study assessed the efficacy and safety of a 2.6% BPO cleanser (Complexion Clearing AV Cleanser, CCAC) in mild-to-moderate AV.</p><p><strong>Methods: </strong>This was a single-center, open-label, 4-week study of subjects aged 18 to 45 years (n=28) with self-perceived sensitive skin and mild-to-moderate AV. CCAC was applied twice daily (morning and evening) on damp skin. Assessments included lesion counts, clinical photography with porphyrin analysis, patient self-assessment questionnaires, collection of adverse events, and standard tolerability ratings.</p><p><strong>Results: </strong>Total lesion counts were significantly reduced by week 1 of CCAC cleanser use (-25.2%, P&lt;0.05). At week 4, AV lesions were numerically reduced but did not reach statistical significance. Additionally, there was a significant reduction of porphyrin counts at week 1 (-19.4% right side face, -28.8% left side, P&lt;0.05 vs baseline). CCAC was well tolerated, with no significant increase in tolerability ratings at any time point compared to baseline, and patients reported good satisfaction.</p><p><strong>Conclusions: </strong>CCAC was efficacious in reducing AV lesions in as little as one week, and a trend in reduction was shown through week 4. Additionally, this 2.6% BPO cleanser was also shown to be very well tolerated and well-liked by subjects with self-perceived sensitive skin. J Drugs Dermatol. 2024;23(9):764-768. doi:10.36849/JDD.8219.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Research to Practice: The Latest Data on Evolving Treatments for Chronic Spontaneous Urticaria. 从研究到实践:慢性自发性荨麻疹治疗方法演变的最新数据。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01
Melinda J Gooderham, Shawn G Kwatra, Bob Geng
{"title":"From Research to Practice: The Latest Data on Evolving Treatments for Chronic Spontaneous Urticaria.","authors":"Melinda J Gooderham, Shawn G Kwatra, Bob Geng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Chronic spontaneous urticaria (CSU) should be on every dermatology practitioner's radar. CSU is a skin disorder marked by wheals, angioedema, or both for more than 6 weeks. Patients with CSU experience unexplained, itchy wheals that appear and disappear, traveling around the body and lasting less than 24 hours per area. Angioedema accompanies wheals for up to 48 hours in around half of cases. CSU is a diagnosis of exclusion, relying heavily on patient history to differentiate CSU symptoms from other causes of urticaria or angioedema. But reassuringly, CSU has a simple diagnostic algorithm and a clear initial treatment path. First-line strategies include non-pharmacologic approaches, and second-generation antihistamines (2gAH) administered up to 4 times their standard dose. Omalizumab and cyclosporine (off-label) are second- and third-line options, respectively. However, many patients will continue to have CSU symptoms despite consistent maximum-dose treatment. Novel therapies, including biologic agents and small molecule drugs targeting mast cell activation and inflammatory mediators, show promise in treating CSU refractory to standard therapy. However, further research is needed to establish their efficacy and safety in clinical practice. J Drugs Dermatol. 2024;23:9(Suppl 2):s5-14.Access the CME Activity.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Skincare Needs of Asians on Reddit Dermatology Social Media Communities: An Observational Study. 评估亚洲人在 Reddit 皮肤科社交媒体社区上的护肤需求:观察研究。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01
Rebecca K Yamamoto, Benjamin A Tran, Michael A Cardis
{"title":"Assessing the Skincare Needs of Asians on Reddit Dermatology Social Media Communities: An Observational Study.","authors":"Rebecca K Yamamoto, Benjamin A Tran, Michael A Cardis","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Steroids Sold as Fade Creams in Beauty Supply Stores: A Danger for Cosmetic Consumers. 美容用品店将局部类固醇作为褪色霜出售:化妆品消费者的危险。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.7608
Janeth R Campbell, Alexandra G Perez, Heather Woolery-Lloyd
{"title":"Topical Steroids Sold as Fade Creams in Beauty Supply Stores: A Danger for Cosmetic Consumers.","authors":"Janeth R Campbell, Alexandra G Perez, Heather Woolery-Lloyd","doi":"10.36849/JDD.7608","DOIUrl":"https://doi.org/10.36849/JDD.7608","url":null,"abstract":"<p><p>Topical corticosteroids are used extensively in dermatology. Class 1 high potency topical steroids (HPTS) can result in unwanted side effects such as skin hypopigmentation, atrophy, and acneiform eruptions. HPTS are only legally available by prescription to ensure appropriate use in the United States (US). The authors have noticed a recent increase in patients presenting with steroid acne after buying HPTS products in beauty supply stores. These products are marketed as fade creams to treat hyperpigmentation and uneven skin tone. We assessed skincare products containing HPTS (clobetasol or betamethasone) in 33 beauty supply stores in Miami, FL; Washington, DC; and Baltimore, MD. Out of 33 beauty supply stores, 14 (42.42%) contained HPTS skincare products, and they were all located in Miami. Out of 15 stores visited in Miami, 14 (93.33%) contained skincare products with clobetasol, and 5 (33.33%) contained skincare products with both clobetasol and betamethasone. Of the stores selling HPTS skincare products, the number of different brands available ranged from 1 to 7, with an average of 4.21 different brands per store. Our study reveals that HPTS are readily available in over-the-counter skincare products in many beauty supply stores. HPTS skincare products were only available in one of three cities suggesting there may be a regional supplier distributing these products. It may also indicate that there is less oversight of retail stores in Miami with HPTS products. More studies are needed to quantify the availability of these products in different locations throughout the US. Further Studies can help identify this problem and raise awareness among consumers of the dangers of HPTS skincare products in beauty supply stores. J Drugs Dermatol. 2024;23(9):709-712. doi:10.36849/JDD.7608.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Algorithmic Beauty: The New Beauty Standard. 算法之美:新的美容标准
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.8074
Alisen Huang, Sabrina Fabi
{"title":"Algorithmic Beauty: The New Beauty Standard.","authors":"Alisen Huang, Sabrina Fabi","doi":"10.36849/JDD.8074","DOIUrl":"https://doi.org/10.36849/JDD.8074","url":null,"abstract":"<p><strong>Background: </strong>Algorithms on various social media platforms feed users what it considers \"beautiful\", impacting the aesthetic desires of patients as well as beauty ideals.</p><p><strong>Objective: </strong>To discuss how algorithms on social media platforms personalize feeds and influence a patient's preference for procedures.</p><p><strong>Methods: </strong>YouTube, Instagram, and TikTok's websites were searched for how their algorithms function. A narrative review of the literature pertaining to social media and cosmetic procedures was also conducted using PubMed.</p><p><strong>Results/discussion: </strong>Social media platforms personalize feeds for their users. Identifying exactly what a patient is exposed to on social media and how that influences their preference for cosmetic procedures presents a challenge at various levels. Social media usage appears to at least influence cosmetic procedure consideration. The desired appearance may be impacted by location, repeated exposure, and familiarity.</p><p><strong>Conclusion: </strong>While impossible to predict the next beauty trend, it is important to understand how algorithms and artificial intelligence may play an increasing role in a patient&rsquo;s visual diet and how their aesthetic goals are thereby affected. Using social media platforms and understanding market trends can guide dermatologists to provide evidence-based education, dispel misinformation, and anchor patients in reality while understanding the cosmetic procedures that patients seek. J Drugs Dermatol. 2024;23(9):742-746.&nbsp; doi:10.36849/JDD.8074.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To Acne and Beyond: A Review of Sarecycline's Off-Label Uses. 痤疮及其他:莎雷环素标示外使用回顾。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01
Savanna I Vidal, Nikita Menta, Adam Friedman
{"title":"To Acne and Beyond: A Review of Sarecycline's Off-Label Uses.","authors":"Savanna I Vidal, Nikita Menta, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions. 局部阿瑞匹坦(HT-001):表皮生长因子受体抑制剂相关丘疹脓疱病的新型疗法。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.8617
Nikita Menta, Savanna I Vidal, Adam Friedman
{"title":"Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions.","authors":"Nikita Menta, Savanna I Vidal, Adam Friedman","doi":"10.36849/JDD.8617","DOIUrl":"10.36849/JDD.8617","url":null,"abstract":"<p><p>Papulopustular eruptions are the most common dermatologic side effect of epidermal growth factor receptor inhibitor (EGFRI) therapy. Topical corticosteroids and oral tetracyclines are frequently used to manage these eruptions, though these treatments are limited by their adverse effects and efficacy. Results from preclinical studies suggest a role for topical aprepitant (HT-001) in the treatment of EGFRI-induced skin toxicities. Herein a case of EGFRI-induced papulopustular eruption with rapid treatment response to topical aprepitant (HT-001) 2% cream is described and the literature reviewed. J Drugs Dermatol. 2024;23(9):e173-e174. doi:10.36849/JDD.8617.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants. 用非烧蚀激光疗法和外用抗氧化剂联合治疗大疱性痤疮相关的炎症后色素沉着。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.8309
Jamie K Hu, Rebecca L Quinonez, Vladimir Antasiuk, Jill Waibel
{"title":"Treatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants.","authors":"Jamie K Hu, Rebecca L Quinonez, Vladimir Antasiuk, Jill Waibel","doi":"10.36849/JDD.8309","DOIUrl":"10.36849/JDD.8309","url":null,"abstract":"<p><p>Acne can cause disfiguring sequelae, such as scarring, post-inflammatory erythema (PIE), and post-inflammatory hyperpigmentation (PIH). These post-inflammatory dyschromias pose a significant psychological burden on patients. This burden disproportionately affects skin of color (SOC) patients and can be the most distressing aspect of acne in SOC patients with skin types IV to VI. Multiple non-ablative lasers are used in the treatment of acne-related PIE and PIH. Combination therapies have shown promise in conditions such as rosacea, acne, and post-inflammatory dyschromia. Addressing both the inflammatory and scarring components of acne is key. Given the role of oxidation in the inflammatory cascade, including antioxidants could be an efficacious adjuvant with non-ablative lasers. This is a single-site, randomized, controlled clinical study of 25 subjects with skin types I to VI with facial PIE and/or PIH from acne. The primary objective was to investigate the clinical efficacy of non-ablative laser therapy followed by the topical application of Silymarin/Salicylic Acid/L-Ascorbic Acid/Ferulic Acid (SSAF) or control in the improvement in oily skin patients with facial PIE and PIH due to acne lesions. There was a statistically significant decrease in PIH and intralesional melanin in patients treated with a combination SSAF and non-ablative laser therapy. Improvement of both PIE and PIH was augmented in combination with SSAF and laser-treated patients compared with the laser-only group, with a concomitant increase in collagen density. This was even more strikingly marked in the SOC subjects, potentially providing an energy-based device (EBD)-based therapy in this population. Limitations of this study include small sample size and length of post-treatment follow-up. J Drugs Dermatol. 2024;23(9):769-773. doi:10.36849/JDD.8309.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Clinical Histology Study Evaluating the Biostimulatory Activity Longevity of Injectable Poly-L-Lactic Acid for Facial Rejuvenation. 一项临床组织学研究,评估用于面部年轻化的注射用聚乳酸的生物刺激活性寿命。
IF 1.5 4区 医学
Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI: 10.36849/JDD.8057
Suleima Arruda, Victor Prieto, Christopher Shea, Alyssa Swearingen, Zahyaa Elmadany, Neil S Sadick
{"title":"A Clinical Histology Study Evaluating the Biostimulatory Activity Longevity of Injectable Poly-L-Lactic Acid for Facial Rejuvenation.","authors":"Suleima Arruda, Victor Prieto, Christopher Shea, Alyssa Swearingen, Zahyaa Elmadany, Neil S Sadick","doi":"10.36849/JDD.8057","DOIUrl":"https://doi.org/10.36849/JDD.8057","url":null,"abstract":"<p><strong>Background: </strong>Poly-L-lactic acid (PLLA) is an injectable filler used for restoring facial fat volume loss that improves skin quality.</p><p><strong>Objective: </strong>To evaluate the histological changes underlying the observed improvement in skin quality after repeated PLLA injections.</p><p><strong>Methods: </strong>Ten healthy women were enrolled in this randomized, placebo-controlled, single-center study. Eligible subjects received 3 treatments every 4 weeks with either PLLA (treatment group) or saline (control group) injections, into both sides of the face. Follow-up visits were at week 18 after the last treatment. Assessments included live ratings, patient questionnaires, three-dimensional microtopography imaging analysis, and histological analysis from biopsies taken before and after PLLA treatment.</p><p><strong>Results: </strong>At the 18-week follow-up, there was a significant improvement in investigator- and subject-rated global aesthetic improvement (GAIS) scores, as well as a decrease in wrinkle severity in PLLA-treated but not placebo-treated patients. Skin quality parameters of erythema, pore size, and roughness were significantly improved from baseline and compared with placebo at the 18-week follow-up as assessed by microtopographic analysis and investigator ratings. Histologic analysis revealed increased tissue remodeling and angiogenesis in PLLA-treated tissues at the 18-week follow-up and decreased elastin fragmentation compared with baseline. No treatment-related adverse events occurred.</p><p><strong>Conclusion: </strong>Repeated PLLA treatments may improve skin quality through tissue remodeling and neovascularization. J Drugs Dermatol. 2024;23(9):729-734. doi:10.36849/JDD.8057.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信